Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we developed an innovative approach in preventing HCV infection using a synergistic combination of a broadly neutralizing human monoclonal antibody (HMAb) targeting the HCV E2 protein and a host-targeting anti-claudin 1 (CLDN1) humanized monoclonal antibody.
|
30599173 |
2019 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of HCV E2 protein in 293 cells was confirmed by western blot analysis. rAAV2/8.HCV E2 vaccine or rAAV2/rh32.33.HCV E2 vaccine was intramuscularly injected into C57BL/6 mice.
|
30569131 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCV E2 protein when associated with CD81 may be responsible for B cell lymphoproliferative disorders, as extrahepatic manifestation.
|
31755827 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Constructs of GrAD and both of its permutated forms fused with the initially insoluble N-terminal fragment of hepatitis C virus' E2 protein were tested.
|
31636289 |
2019 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, selective neutralizing human monoclonal antibodies (HuMAbs) targeting conserved antigenic domain B and D epitopes of the E2 protein bound strongly to the HCV VLPs, suggesting that these critical epitopes are expressed on the surface of the particles.
|
29691437 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intrinsic structural versatility of the highly conserved 412-423 epitope of the Hepatitis C Virus E2 protein.
|
29758309 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acquisition of resistance to bNAbs by some autologous strains was accompanied by progressive loss of E2 protein function, and temporally associated with HCV clearance.
|
30439341 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this regard, we have studied the mechanism underlying the HCV fusion process using liposomes and a truncated form of E2 protein lacking the transmembrane region, E2<sub>661</sub> (amino acids 384-661).
|
29273334 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCV E2 protein mimicked GPC3 and led to enhanced Hippo activity and decreased YAP in cultured normal human hepatocytes.
|
29577937 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCV Core protein has been associated with the modulation of potentially oncogenic cellular processes and E2 protein has been useful in evolutive studies to analyze the diversity of HCV.
|
27163636 |
2017 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Antigenic determinants generating the neutralizing antibodies from these two samples were delineated by epitope mapping using the core, E1 and E2 regions and a stretch of 45 amino acid peptide (E2C45) derived from the C-terminal region of HCV-E2 protein (aa 634-679) was designed.
|
28221101 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies have indicated that interactions between the HCV E2 protein and CD81 on host cells are required for HCV infection.
|
28481946 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human thyroid cell lines ML-1 and human thyrocytes in primary cell culture were treated with HCV recombinant E2 protein.
|
27860532 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Present data also suggest that the strict conservation of Gly436 in E2 protein of different HCV genotypes is likely dictated by structural restraints.
|
26973093 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HC33.4 and AR4A are two of the most potent anti-HCV human bNAbs characterized to date, binding to highly conserved epitopes near the amino- and carboxy-terminus of HCV envelope (E2) protein, respectively.
|
28235087 |
2017 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Re-exposure of convalescent (cured) B cells to viremic plasma and recombinant HCV E2 protein led to re-expression of T-bet.
|
27925349 |
2017 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using HCV-like particles (HCV-LPs) corresponding to genotype 3a (prevalent in India), we obtained three mAbs specific for the E2 protein that significantly inhibited virus binding to hepatoma cells.
|
27574733 |
2016 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunoprecipitation analysis revealed that AP1S3 interacted with the HCV E2 protein.
|
27079945 |
2016 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These cells proliferated prominently through the early expression of interleukin-10 and intracellular latent membrane protein (LMP)-l. By contrast, the overexpression of CD81 on EBV-transformed B cells by anti-CD81 mAb or HCV E2 protein induced apoptosis through reactive oxygen species (ROS)-mediated mitochondrial dysfunction.
|
26498453 |
2015 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surface plasmon resonance detection was used to screen the ligand set for binding to recombinant E2 protein, and the best binders were subsequently tested to identify compounds that inhibit the infection of Huh-7 cells by HCV.
|
25357246 |
2014 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similar results were obtained for the other HIV-1 proteins Vif and Vpr, whereas no differences were obtained in the number of epitopes for the hepatitis C virus E1/E2 protein sequence or for the scrambled HIV-1 sequence.
|
24954875 |
2014 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate and compare the inflammatory response of endothelial cells to two recombinant forms of the HCV E2 protein produced in different expression systems (Escherichia coli and Pichia pastoris).
|
25317702 |
2014 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, a novel host factor CD63 was shown to directly interact with HCV E2 protein.
|
23593195 |
2013 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our mutagenesis analyses of HCV pseudoparticles and cell culture-derived HCV using the H77 isolate indicate that five residues at positions 14, 15, and 25-27 mediate binding of the E2 protein to the scavenger receptor class B, type I receptor, and any residue herein is indispensable for HCV cell entry.
|
22927442 |
2012 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus E2 protein involve in insulin resistance through an impairment of Akt/PKB and GSK3β signaling in hepatocytes.
|
22721429 |
2012 |